This was confirmation, not an upside surprise. GPGI explicitly characterized second-quarter performance as “in-line with revised guidance” and reiterated its full-year targets; no independent consensus is provided in the filing, so a precise beat or miss cannot be substantiated. The net message versus the standing expectation is therefore largely a meet, not a positive reset. (2Q26 Financial Performance; Reiterating FY26 Guidance)
| Metric | 2Q25 | 2Q26 | FY26 guidance |
|---|---|---|---|
| Pro Forma Adjusted Net Sales | $493.7m | $473.2m | $1,950m–$2,100m |
| Pro Forma Adjusted EBITDA | $130.2m | $113.9m | $550m–$610m |
| Pro Forma Adjusted EBITDA margin | 26.4% | 24.1% | 27.0%–29.0% |
| CompoSecure adjusted net sales | $119.6m | $133.6m | — |
| CompoSecure Pro Forma Adjusted EBITDA | $48.6m | $55.2m | — |
| Husky adjusted net sales | $374.1m | $339.6m | — |
| Husky Pro Forma Adjusted EBITDA | $83.9m | $64.9m | — |
| Adjusted diluted EPS | $0.25 | $0.17 | — |
| Pro Forma Adjusted Free Cash Flow, YTD | — | $92.1m | $275m–$325m |
CompoSecure is the genuine bright spot, but it was not enough to lift the consolidated result. Sales rose 11.7%, EBITDA increased 13.6%, and margin expanded to 41.3% from 40.6%, indicating that demand and operating improvements are translating into incremental profit rather than merely revenue growth. (CompoSecure 2Q26 Financial Performance)
Husky remains the key execution risk and makes the recovery heavily second-half dependent. Revenue fell 9.2%, EBITDA dropped 22.6%, and margin contracted to 19.1% from 22.4% as lower systems and hot-runner sales created negative fixed-cost leverage. The sequential rebound from first quarter is encouraging, but the full-year plan still requires demand recovery, cost savings, and better factory absorption in the second half. (Husky 2Q26 Summary; Husky 2Q26 Financial Performance)
The guidance framework is intact, but the evidence supporting it is still prospective. Management continues to expect flat organic revenue, roughly 7% EBITDA growth at the midpoint, and second-half margin expansion. However, Husky’s order recovery is described as initial, while adjusted free cash flow was $92.1 million through six months against a $275 million–$325 million full-year target; the company also ended June with $2.0 billion of net debt and 3.9x net leverage. That leaves the filing as a mixed operational read: strong execution at CompoSecure, offset by a Husky rebound that remains to be delivered. (Reiterating FY26 Guidance; 2Q26 Earnings Per Share and Adjusted Free Cash Flow Non-GAAP Reconciliation; Capital Structure Update)
Read the original 8-K on SEC EDGAR ↗